Overview
Binds to GHS-R1a receptors to stimulate GH release and activate orexigenic pathways.
Proposed mechanism
Synthetic hexapeptide acting on ghrelin receptor (GHS-R1a) in pituitary and hypothalamus.
What the evidence supports
Most data comes from preclinical animal studies. Human clinical trial evidence is limited or absent.
Graded Animal
Evidence drawn from in vivo animal models or in vitro systems. Mechanistically informative; translation to humans is unproven.
Key citations
Representative primary sources, including results that did not favour the compound.
- [1]
GHRP-6 and GH release
· DOI:10.1210/jcem.86.9.7803 · 2001
- [2]
GHRP-6 and GH release (2001)
· · 0
Citation records in this build are illustrative placeholders for the design.
Reference information for research purposes. Not medical advice, and not a recommendation to use any compound. Many entries describe substances that are not approved for human use.